Nuclear Receptor Imaging In Vivo—Clinical and Research Advances
Open Access
- 31 December 2022
- journal article
- review article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (3), bvac197
- https://doi.org/10.1210/jendso/bvac197
Abstract
Nuclear receptors are transcription factors that function in normal physiology and play important roles in diseases such as cancer, inflammation, and diabetes. Noninvasive imaging of nuclear receptors can be achieved using radiolabeled ligands and positron emission tomography (PET). This quantitative imaging approach can be viewed as an in vivo equivalent of the classic radioligand binding assay. A main clinical application of nuclear receptor imaging in oncology is to identify metastatic sites expressing nuclear receptors that are targets for approved drug therapies and are capable of binding ligand to improve treatment decision making. Research applications of nuclear receptor imaging include novel synthetic ligand and drug development by quantifying target drug engagement with the receptor for optimal therapeutic drug dosing and for fundamental research into nuclear receptor function in cells and animal models. This Mini-Review provides an overview of PET imaging of nuclear receptors with a focus on radioligands for estrogen receptor, progesterone receptor, and androgen receptor and their use in breast and prostate cancer.Funding Information
- American Cancer Society (RSG-22-015-01-CCB)
- NIH/NCI (1R01CA272571-01)
This publication has 160 references indexed in Scilit:
- Synthesis and evaluation of 18F-labeled PPARγ antagonistsNuclear Medicine and Biology, 2012
- Activation of the Glucocorticoid Receptor Is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast CancerCancer Research, 2011
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health StudyLaboratory Investigation, 2011
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Imaging Progesterone Receptor in Breast Tumors: Synthesis and Receptor Binding Affinity of Fluoroalkyl-Substituted Analogues of TanaprogetJournal of Medicinal Chemistry, 2010
- Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-γ ligands: potential positron emission tomography imaging agentsNuclear Medicine and Biology, 2009
- ERβ in breast cancer—Onlooker, passive player, or active protector?Steroids, 2008
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- Predicting Response to Endocrine Therapy in Human Breast Cancer: A HypothesisScience, 1975
- On the Origin of Cancer CellsScience, 1956